Cefotaxime
規格
63527-52-6CAS番号
264-299-1EC番号
(6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acidIUPAC名
C16H17N5O7S2化学式
455.5 g/mol分子量
cefotaxime; 63527-52-6; Cephotaxime; Cefotaxima; Cefotaximum; Cefotaxim Hikma; CHEBI:204928; N2GI8B1GK7; (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; DTXSID6022761; Cefotaxim; (6R,7R)-3-[(acetyloxy)methyl]-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-Acetoxymethyl-7-{2-(2-amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6R-(6alpha,7beta(Z)))-; Cephotaxim; Klaforan; Primafen; (6R,7R)-3-((acetyloxy)methyl)-7-((2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-3-(acetoxymethyl)-7-(((2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-3-(acetoxymethyl)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(acetyloxymethyl)-7-(((2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-3-Acetoxymethyl-7-(2-(2-amino-thiazol-4-yl)-2-((Z)-methoxyimino)-acetylamino)-8-oxo-5-thia-1-aza-bicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo(4.2.0)oct-2-ene-2-carboxylic acid; RefChem:54734; J01DA10; DTXCID501476108; 264-299-1; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, monosodium salt, (6R-(6alpha,7beta(Z)))-; Claforan; Cefotaxime acid; 60846-21-1; MFCD00864971; Cefotaxime (INN); CEFOTAXIME [INN]; Omnatax; Taxim; (6R,7R)-3-(acetoxymethyl)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-(((2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6R,7R)-; C16H17N5O7S2; Cefotaxime [INN:BAN]; Cefotaximum [INN-Latin]; Cefotaxima [INN-Spanish]; UNII-N2GI8B1GK7; Cefotaxima acid; 4kot; (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-ethanoyl]amino]-8-oxo-5-thia-1-azabicy clo[4.2.0]oct-2-ene-2-carboxylic acid; 1056874-43-1; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, (6R,7R)-; EINECS 264-299-1; Cefotaxime acid CRS; RU 24662; CEFOTAXIME [MI]; CEFOTAXIME [JAN]; Prestwick2_000139; Prestwick3_000139; CEFOTAXIME [VANDF]; Epitope ID:174838; Claforan (*Sodium salt*); CEFOTAXIME [WHO-DD]; CHEMBL1730; Lopac0_000278; BSPBio_000218; Cefotaxime sodium salt sterile; BPBio1_000240; orb1299554; orb3025810; SCHEMBL3731931; GTPL10893; HY-A0088A; HMS2090M11; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-8-oxo-, (6R,7R)-; MSK10011; AC-217; BDBM50482777; EBC-27144; s4720; AKOS015951267; AC37153; DB00493; SDCCGSBI-0050266.P002; 3-(Acetyloxymethyl)-7-(((2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-acetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; AS-12690; DA-51752; clo[4.2.0]oct-2-ene-2-carboxylic acid; C1632; CS-0013515; NS00098722; T7733; C06885; D07647; G12689; EN300-21702510; Q417968; BRD-K78364995-236-03-5; BRD-K78364995-236-16-7; BRD-K78364995-236-17-5; Di-|I-chlorotetrakis[2,4-dimethyl-6-(2-quinolinyl-KN)phenyl-KC]di-iridium; (6R,7R)-3-(Acetoxymethyl)-7-((2-(2-amino-4-thiazolyl)-2-methoxyiminoglyoxylamino)-8-oco-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-3-(acetoxymethyl)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-ethanoyl]amino]-8-oxo-5-thia-1-azabicy; (6R,7R,Z)-3-(ACETOXYMETHYL)-7-(2-(2-AMINOTHIAZOL-4-YL)-2-(METHOXYIMINO)ACETAMIDO)-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID別名
Cefotaximeを含む製品
VALORAN 2 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFGVALORAN 1 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFGCEFOTAXIMA TORLAN 500 MG POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE IV/IM EFGCEFOTAXIMA TORLAN 2000 MG POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFGCEFOTAXIMA TORLAN 1000 MG POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE IV/IM EFGCEFOTAXIMA TORLAN 1000 MG POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE IM EFGAntifoxim 1gAurocefaBecrazBigunatCefofastCefotamid
1/13ページ
Cefotaximeを販売する企業
CT
Công Ty Cổ Phần Dược Phẩm Tv.Pharm Viet NamCT
Công ty TNHH Phil Inter PharmaViet Nam1/7ページ